Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by two types of lesions in the brain: extracellular senile plaques consisting of APP-derived amyloid ß (Aß) peptide and intracellular neurofibrillary tangles build out of hyperphosphorylated microtubule-associated tau protein. 

One process that could contribute to memory loss in AD due to synapse loss and neuronal cell death is the intracellular caspase cleavage of the amyloid precursor protein (APP), producing APP delta C31 and C31.

This review focuses on a high-throughput screening of small molecules that inhibit the APP-C31 generating cleavage pathway as part of AD drug discovery.

Read the full story!